HumanCo Acquisition Corp. P.O. Box 90608 Austin, TX 78709 Re: Initial Public Offering Ladies and Gentlemen:
Exhibit 10.1
[●], 2020
HumanCo Acquisition Corp.
P.O. Box 90608
P.O. Box 90608
Austin, TX 78709
Re: Initial Public Offering
Ladies and Gentlemen:
This letter (this “Letter Agreement”)
is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) to be entered into by
and between HumanCo Acquisition Corp., a Delaware corporation (the “Company”), and Citigroup Global Markets Inc., as
underwriter (the “Underwriter”), relating to an underwritten initial public offering (the “Public Offering”) of 22,500,000 of the Company’s units (including up to 3,375,000 units that may be purchased by the Underwriter to cover over-allotments,
if any) (the “Units”), each comprising one share of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), and one-half of one redeemable warrant. Each whole warrant (each, a “Warrant”) entitles the holder thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment. The Units will be sold in the Public
Offering pursuant to a registration statement on Form S-1 and a prospectus (the “Prospectus”), filed by the Company with the
U.S. Securities and Exchange Commission (the “Commission”) and the Company has applied to have the Units listed on The Nasdaq
Capital Market. Certain capitalized terms used herein are defined in paragraph 11 hereof.
In order to induce the Company and the Underwriter to enter into the Underwriting Agreement and to proceed with the Public Offering, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of HumanCo Acquisition Holdings, LLC (the “Sponsor”),
HMCO Acquisition, LLC (“HumanCo SPV”), CAVU Venture Partners III, LP (“CAVU”) and the undersigned individuals, each of whom is a member of the Company’s board of directors and/or management team (each, an “Insider” and collectively, the “Insiders”),
xxxxxx agrees with the Company as follows:
|
1.
|
The Sponsor, HumanCo SPV, CAVU and each Insider hereby agrees that in the event that the Company fails to consummate a Business Combination within
24 months from the closing of the Public Offering, or such later period approved by the Company’s stockholders in accordance with the Company’s amended and restated certificate of incorporation (the “Charter”), the Sponsor, HumanCo SPV, CAVU and each Insider shall take all reasonable steps to cause the Company to (i) cease all operations
except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than 10 Business Days thereafter, subject to lawfully available funds therefor, redeem 100% of the Common Stock sold as part of the Units in the
Public Offering (the “Offering Shares”) and the Common Stock sold as part of the CAVU Units (the “CAVU Shares”), at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account
(as defined below), including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by
the number of then outstanding Offering Shares and CAVU Shares, which redemption will completely extinguish all Public Stockholders’ and holders of CAVU Shares’ rights as stockholders (including the right to receive further liquidation
distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and
liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and other requirements of applicable law. The Sponsor, HumanCo SPV, CAVU and each Insider agrees not to propose any amendment
to the Charter to (a) modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or the Company’s obligation to redeem 100% of the Offering Shares and CAVU Shares if the Company
does not complete a Business Combination within the time period set forth in the Charter or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provides
Public Stockholders with the opportunity to redeem their shares of Common Stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account (excluding any
amounts then on deposit in the Trust Account that are allocable to the CAVU Shares), including interest earned on the funds held in the Trust Account (which interest shall be net of taxes payable and excluding any interest earned on the
funds held in the Trust Account that are allocable to the CAVU Shares) and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding Offering Shares.
|
The Sponsor, HumanCo SPV, CAVU and each Insider acknowledges that, with respect to the Founder Shares held by it, him or her, it, he or she
has no right, title, interest or claim of any kind in or to any monies held in the Trust Account as a result of any liquidation of the Company, it being understood that CAVU makes no such acknowledgement with respect to the CAVU Shares in the event
of any liquidation of the Company. The Sponsor, HumanCo SPV, CAVU and each Insider hereby agrees that if the Company seeks stockholder approval of a proposed Business Combination, then in connection with such proposed Business Combination, it, he or
she shall vote any shares of Capital Stock (whether purchased before, during or after the Public Offering, including in open market and privately negotiated transactions) owned by it, him or her in favor of any proposed Business Combination. The
Sponsor, HumanCo SPV, CAVU and each Insider hereby further waives, with respect to any shares of Capital Stock held by it, him or her (including, for the avoidance of doubt, the CAVU Shares), if any, any redemption rights it, he or she may have in
connection with the consummation of a Business Combination, including, without limitation, any such rights available in the context of (i) a stockholder vote to approve such Business Combination, or (ii) a stockholder vote to approve an amendment to
the Charter to (a) modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Offering Shares and CAVU Shares if the Company does not complete a Business
Combination within the time period set forth in the Charter or (b) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity (although the Sponsor, HumanCo SPV, CAVU and the Insiders shall be
entitled to liquidation rights with respect to any Offering Shares and CAVU Shares it or they hold if the Company fails to consummate a Business Combination within the time period set forth in the Charter). If the Company engages in a tender offer in
connection with any proposed Business Combination, the Sponsor, HumanCo SPV, CAVU and each Insider agrees that it, he or she will not seek to sell its, his or her shares of Capital Stock to the Company in connection with such tender offer.
|
2.
|
The undersigned acknowledges and agrees that prior to entering into a definitive agreement for a Business Combination or subsequent transaction with
a target business that is affiliated with the undersigned or any other Insiders of the Company or their affiliates, such transaction must be approved by a majority of the Company’s disinterested independent directors and the Company, or a
committee of independent directors, must, to the extent required by applicable law or based upon the direction of the Company’s board of directors or a committee thereof, obtain an opinion from an independent investment banking firm or
another entity that commonly renders valuation opinions that such Business Combination or transaction is fair to the Company from a financial point of view.
|
|
3.
|
During the period commencing on the date of the Underwriting Agreement and ending 180 days after such date, the Sponsor, HumanCo SPV, CAVU and each
Insider shall not, without the prior written consent of the Underwriter, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or
indirectly, any Units, CAVU Units, shares of Common Stock, Founder Shares, Warrants, Private Placement Warrants, CAVU Warrants or any securities convertible into, or exercisable or exchangeable for, shares of Common Stock owned by it, him
or her, (ii) establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the Commission promulgated thereunder, with respect to any Units, CAVU Units, shares of Common
Stock, Founder Shares, Warrants, Private Placement Warrants, CAVU Warrants or any securities convertible into, or exercisable or exchangeable for, shares of Common Stock (but excluding Units and shares of Common Stock purchased in the
Public Offering or thereafter) owned by it, him or her, (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Units, CAVU Units, shares of Common
Stock, Founder Shares, Warrants, Private Placement Warrants, CAVU Warrants or any securities convertible into, or exercisable or exchangeable for, shares of Common Stock owned by it, him or her, whether any such transaction is to be settled
by delivery of such securities, in cash or otherwise, or (iv) publicly announce any intention to effect any transaction specified in clause (i) , (ii) or (iii). The provisions of this paragraph will not apply if the release or waiver is
effected solely to permit a transfer not for consideration and the transferee has agreed in writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms remain in effect at the
time of the transfer.
|
2
|
4.
|
In the event of the liquidation of the Trust Account upon the failure of the Company to consummate its initial Business Combination within the time
period set forth in the Charter, the Sponsor (the “Indemnitor”), which for purposes of clarification shall not extend
to any shareholders, members or managers of the Sponsor, or any of the other undersigned, agrees to indemnify and hold harmless the Company against any and all loss, liability, claim, damage and expense whatsoever (including, but not
limited to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, whether pending or threatened) to which the Company may become subject as a result of any claim by (i) any
third party for services rendered or products sold to the Company or (ii) any prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or Business Combination
agreement (a “Target”); provided,
however, that such indemnification of the Company by the Indemnitor (x) shall apply only to the extent necessary to ensure that such claims by a
third party for services rendered (other than the Company’s independent public accountants) or products sold to the Company or a Target do not reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Offering
Share and CAVU Share and (ii) the actual amount per Offering Share and CAVU Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Offering Share and CAVU Share is then held in the
Trust Account due to reductions in the value of the trust assets, less interest earned on the funds in the Trust Account which may be withdrawn to pay franchise and income taxes, (y) shall not apply to any claims by a third party or a
Target which executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) and (z) shall not apply to any claims under the Company’s indemnity of the Underwriter against certain
liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The
Indemnitor shall have the right to defend against any such claim with counsel of its choice reasonably satisfactory to the Company if, within 15 days following written receipt of notice of the claim to the Indemnitor, the Indemnitor
notifies the Company in writing that it shall undertake such defense.
|
|
5.
|
To the extent that the Underwriter does not exercise its over-allotment option to purchase up to an additional 3,375,000 Units within 45 days from
the date of the Prospectus (and as further described in the Prospectus) in full, the Sponsor agrees to forfeit, at no cost, a number of Founder Shares in the aggregate equal to 843,750 multiplied by a fraction (i) the numerator of which is
3,375,000 minus the number of Units purchased by the Underwriter upon the exercise of its over-allotment option, and (ii) the denominator of which is 3,375,000. For clarity, the forfeiture shall yield the result that the Initial
Stockholders will own an aggregate of 20% of the Company’s issued and outstanding shares of Capital Stock after the Public Offering (excluding the CAVU shares and assuming that the Initial Stockholders do not purchase any Units in the
Public Offering).
|
|
6.
|
The Sponsor, HumanCo SPV, CAVU and each Insider hereby agrees and acknowledges that: (i) the Underwriter and the Company would be irreparably
injured in the event of a breach by such Sponsor, HumanCo SPV, CAVU or an Insider of its, his or her obligations under paragraphs 1, 2, 3, 4, 5, 6, 7(a), 7(b) and, solely as to each D&O Insider, 8, as applicable, of this Letter
Agreement, (ii) monetary damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall be entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity, in the
event of such breach.
|
3
|
7.
|
(a) The Sponsor, HumanCo SPV, CAVU and
each Insider agrees that it, he or she shall not Transfer any Founder Shares or CAVU Shares (or shares of Common Stock issuable upon conversion thereof) until the earlier of (A) one year after the completion of the Company’s initial
Business Combination or (B) subsequent to the Company’s initial Business Combination, (x) if the last reported sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial Business Combination or (y) the date on which the Company completes a
liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property
(the “Founder Shares Lock-up Period”).
|
|
|
(b) The Sponsor, HumanCo SPV, CAVU and each Insider agrees that it, he or she shall not Transfer any Private Placement Warrants or CAVU
Warrants (or shares of Common Stock issued or issuable upon the exercise thereof) until 30 days after the completion of the Company’s initial Business Combination (the “Private Placement Warrants Lock-up Period”, together with the Founder Shares Lock-up Period, the “Lock-up Periods”).
|
|
|
(c) Notwithstanding the provisions set forth in paragraphs 7(a) and (b), Transfers of the Founder Shares, CAVU Shares, Private Placement
Warrants, CAVU Warrants and shares of Common Stock issued or issuable upon the exercise or conversion thereof and, with respect to the Founder Shares, Private Placement Warrants and shares of Common Stock issued or issuable upon the
exercise or conversion thereof, that are held by the Sponsor, HumanCo SPV, CAVU, any Insider or any of their permitted transferees (that have complied with this paragraph 7(c)), are permitted (a) to the Company’s officers or directors, any
affiliates or family members of any of the Company’s officers or directors, the Sponsor, any members of the Sponsor, any affiliates of the Sponsor or CAVU, or any affiliates of such members and funds and accounts advised by such members or
any limited partners of any such funds that are invested in the Sponsor or the limited partners of CAVU; (b) in the case of an individual, by gift to a member of such individual’s immediate family or to a trust, the beneficiary of which is
a member of such individual’s immediate family, an affiliate of such individual or to a charitable organization; (c) in the case of an individual, by virtue of the laws of descent and distribution upon death of the individual; (d) in the
case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with the consummation of an initial Business Combination at prices no greater than the price at which the Founder
Shares, CAVU Shares, Private Placement Warrants, CAVU Warrants or shares of Common Stock were originally purchased; (f) to an entity that is an affiliate of the holder; (g) in the event of the Company’s liquidation prior to the completion
of an initial Business Combination; (h) by virtue of the laws of the State of Delaware or the Sponsor’s limited liability company agreement upon dissolution of the Sponsor; (i) in the event of the Company’s liquidation, merger, capital
stock exchange, reorganization or other similar transaction which results in all of the Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property subsequent to the completion of
an initial Business Combination; or (j) to the Company for no value for cancellation in connection with the consummation of the initial Business Combination; provided, however, that, in the case of clauses (a) through (f) or (h), these
permitted transferees must enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this paragraph 7(c) and the other restrictions contained in this Letter Agreement.
|
|
8.
|
Each of the Insiders who is or is nominated to be a director or officer of the Company (each, a “D&O Insider”) agrees to serve in such capacity until the earlier of the consummation by the Company of an initial Business Combination, the liquidation of the
Company, or his or her removal, death or incapacity. The Sponsor, HumanCo SPV, CAVU and each D&O Insider represents and warrants that it, he or she has never been suspended or expelled from membership in any securities or commodities
exchange or association or had a securities or commodities license or registration denied, suspended or revoked. Each D&O Insider’s biographical information furnished to the Company (including any such information included in the
Prospectus) is true and accurate in all material respects and does not omit any material information with respect to the D&O Insider’s background and contains all of the information required to be disclosed pursuant to Item 401 of
Regulation S-K, promulgated under the Securities Act. Each D&O Insider’s questionnaire furnished to the Company and the Underwriter is true and accurate in all material respects. Each D&O Insider represents and warrants that: it,
he or she is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction;
it, he or she has never been convicted of, or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities; and
it, he or she is not currently a defendant in any such criminal proceeding.
|
4
|
9.
|
Except as disclosed in the Prospectus, neither the Sponsor, HumanCo SPV, CAVU nor any Insider, nor any affiliate of the Sponsor, HumanCo SPV, CAVU
or any Insider, shall receive from the Company any finder’s fee, reimbursement, consulting fee, monies in respect of any repayment of a loan or other compensation prior to, or in connection with any services rendered in order to effectuate,
the consummation of the Company’s initial Business Combination (regardless of the type of transaction that it is).
|
|
10.
|
The Company, the Sponsor, HumanCo SPV, CAVU and each Insider represents and warrants, severally and not jointly, that it, he or she has full right
and power, without violating any agreement to which it, he or she is bound (including, without limitation, any non-competition or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement and, as
applicable, to serve as an officer and/or director on the board of directors of the Company and hereby consents to being named in the Prospectus as an officer and/or director of the Company.
|
|
11.
|
As used herein, (i) “Business
Combination” shall mean a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses; (ii) “Business Day” means each day that is not
a Saturday, Sunday or other day on which banking institutions in The City of New York, New York, are authorized or required by law to close; (iii) “CAVU Units” shall mean the units, each identical to the Units except as described in the Prospectus, that CAVU has agreed to purchase for an aggregate purchase price of $25,000,000, or $1.00 per unit, in
a private placement that shall occur simultaneously with the consummation of the Public Offering; (iv) “CAVU Warrants”
shall mean the warrants to purchase up to 1,250,000 shares of Common Stock of the Company that are included in the CAVU Units; (v) “Capital Stock” shall mean, collectively, the Common Stock and the Founder Shares; (vi) “Founder Shares”
shall mean the 6,468,750 shares of the Company’s Class B common stock, par value $0.0001 per share, initially issued to the Sponsor (up to 843,750 shares
of which are subject to complete or partial forfeiture by the Sponsor if the over-allotment option is not exercised in full by the Underwriter) outstanding immediately prior to the consummation of the Public Offering; (vii) “Initial Stockholders” shall mean the Sponsor and any Insider that holds Founder Shares prior to the consummation of the
Public Offering; (viii) “Private Placement Warrants” shall mean the Warrants to purchase up to 6,825,000 shares of
Common Stock of the Company (or 7,500,000 shares of Common Stock if the over-allotment option is exercised in full by the Underwriter) that the Sponsor has agreed to purchase for an aggregate purchase price of $6,825,000 (or $7,500,000 if
the over-allotment option is exercised in full by the Underwriter), or $1.00 per Warrant, in a private placement that shall occur simultaneously with the consummation of the Public Offering; (ix) “Public Stockholders” shall mean the holders of the Offering Shares; (x) “Trust Account” shall mean the trust account into which the net proceeds of the Public Offering, the sale of the CAVU Units and certain proceeds from the sale of the Private Placement Warrants
shall be deposited; and (xi) “Transfer” shall mean the (a) sale of, offer to sell, contract or agreement to sell,
hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call
equivalent position within the meaning of Section 16 of the Exchange Act, and the rules and regulations of the Commission promulgated thereunder with respect to, any security, (b) entry into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement of any intention to
effect any transaction specified in clause (a) or (b).
|
5
|
12.
|
The Company will maintain an insurance policy or policies providing directors’ and officers’ liability insurance, and each D&O Insider shall be
covered by such policy or policies, in accordance with its or their terms, to the maximum extent of the coverage available for any of the Company’s directors or officers.
|
|
13.
|
This Letter Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and
supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Letter
Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument executed by all parties hereto.
|
|
14.
|
No party hereto may assign either this Letter Agreement or any of its rights, interests, or obligations hereunder without the prior written consent
of the other parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be
binding on the Company, the Sponsor and each Insider and their respective successors, heirs and assigns and permitted transferees.
|
|
15.
|
Nothing in this Letter Agreement shall be construed to confer upon, or give to, any person or corporation other than the parties hereto any right,
remedy or claim under or by reason of this Letter Agreement or of any covenant, condition, stipulation, promise or agreement hereof. All covenants, conditions, stipulations, promises and agreements contained in this Letter Agreement shall
be for the sole and exclusive benefit of the parties hereto and their successors, heirs, personal representatives and assigns and permitted transferees.
|
|
16.
|
This Letter Agreement may be executed in any number of original, facsimile or other electronic counterparts and each of such counterparts shall for
all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.
|
|
17.
|
This Letter Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Letter Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of
this Letter Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.
|
|
18.
|
This Letter Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to
conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereto (i) all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to,
this Letter Agreement shall be brought and enforced in the courts of New York City, in the State of New York, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii) waive any
objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.
|
|
19.
|
Any notice, consent or request to be given in connection with any of the terms or provisions of this Letter Agreement shall be in writing and shall
be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or facsimile or e-mail transmission.
|
|
20.
|
This Letter Agreement shall terminate on the earlier of (i) the expiration of the Lock-up Periods or (ii) the liquidation of the Company; provided
that paragraph 4 of this Letter Agreement shall survive such liquidation.
|
[Remainder of page intentionally left blank]
6
|
Sincerely,
|
|||
|
HUMANCO ACQUSITION HOLDINGS, LLC
|
|||
|
By:
|
|||
|
Name:
|
|||
|
Title:
|
|||
|
HMCO ACQUISITION, LLC
|
|||
|
By:
|
|||
|
Name:
|
|||
|
Title:
|
|||
|
CAVU VENTURE PARTNERS III, LP
|
|||
|
By: CAVU Venture Partners GP III, LP
|
|||
|
Its: General Partner
|
|||
|
By: CAVU Venture Partners GP III, LLC
|
|||
|
Its: General Partner
|
|||
|
By:
|
|||
|
Name:
|
|||
|
Title:
|
|||
|
Xxxxx X. Xxxx
|
|
|
Xxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx
|
|
|
Xxx Xxxxxx
|
|
|
Xxxxx Xxx
|
|
|
Xxxxxxx Xxxx
|
|
|
Xxxx Xxxxxxx
|
[Signature Page to Letter Agreement]
|
Xxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx
|
|
Acknowledged and Agreed:
|
|||
|
By:
|
|||
|
Name:
|
|||
|
Title:
|
|||
[Signature Page to Letter Agreement]
